Studies presented here introduce another perspective on the mechanisms responsible for IgM autoantibody production. A unique subpopulation of B lymphocytes (Ly-1 B) that concomitantly expresses IgM, IgD, Ia, and Ly-1 membrane glycoproteins is present at higher frequencies in NZB and NZB-related mice. The Ly-1 B subpopulation in these autoimmune dinials is responsible for the "spontaneous" IgM secretion demonstrated with cultured JNZB spleen cells and contains the cells that secrete typical NZB IgM autoantibodies to single-stranded DNA and to thymocytes. In addition, the Ly-1 B population in normal mouse strains (and in NZB) contains virtually all of the spleen cells that secrete IgM autoantibodies reactive with bromelain-treated mouse erythrocytes. Since a different B-cell subpopulation (IgM+, Ig-, Ly-lE) (11) . This Ly-1 B subpopulation (11, 12), which is also marked by characteristic levels of surface IgM and IgD, is present at increased frequencies in NZB and NZB-related autoimmune mice (e.g., 5-10% in NZB spleen compared with 1-2% in BALB/c spleen). Furthermore, it tends to be more active in NZB in the sense that Ly-1 B cells sorted from these animals spontaneously secrete much more IgM in vitro than BALB/c Ly-1 B cells sorted and cultured at the same density (11).
cells and contains the cells that secrete typical NZB IgM autoantibodies to single-stranded DNA and to thymocytes. In addition, the Ly-1 B population in normal mouse strains (and in NZB) contains virtually all of the spleen cells that secrete IgM autoantibodies reactive with bromelain-treated mouse erythrocytes. Since a different B-cell subpopulation (IgM+, Ig-, Ly-lE) secretes most of the IgM antibodies produced in responses to exogenous antigens, we conclude that Ly-l B cells constitute a functionally distinct B-cell population important in certain kinds of autoimmunity.
NZB mice have characteristically increased serum IgM levels and produce relatively large amounts of IgM autoantibodies to cell surface determinants (e.g., on erythrocytes and thymocytes) and to DNA (1) (2) (3) (4) . In addition, these mice have splenic B cells that spontaneously secrete IgM when cultured in the absence of exogenously added mitogens. BALB/c mice, in contrast, have low serum IgM levels and do not normally produce very much IgM (or IgG) autoantibody. Furthermore, splenic B cells from these animals do not spontaneously secrete IgM in vitro.
The hyperactive behavior of NZB B cells is approximated by BALB/c B cells that have been stimulated with LPS (a lipopolysaccharide commonly used in vitro as a polyclonal B cell activator). BALB/c spleen cells cultured with LPS, for example, divide and differentiate to IgM-secreting cells. Similarly, BALB/c mice injected with LPS rapidly initiate production of IgM autoantibodies that NZB mice produce constitutively-e.g., those that detect a cryptic antigen revealed on mouse erythrocytes by proteolytic treatment with the enzyme bromelain (5-10). Thus, with respect to B-cell activation and functional differentiation, the NZB autoimmune disorder would appear to mimic the effects of LPS stimulation on normal B cells (1, 2, 10) .
Recent fluorescence-activated cell sorter (FACS) studies suggest that this hypothesis applies more accurately to a relatively rare B cell subpopulation rather than to B cells in general. Using two-color FACS analysis and sorting, we have shown that the NZB B cells that spontaneously secrete IgM in vitro belong to a distinct splenic B cell subpopulation that carries the Ly-1 surface marker previously considered unique to T cells (11) . This Ly-1 B subpopulation (11, 12) , which is also marked by characteristic levels of surface IgM and IgD, is present at increased frequencies in NZB and NZB-related autoimmune mice (e.g., 5-10% in NZB spleen compared with 1-2% in BALB/c spleen). Furthermore, it tends to be more active in NZB in the sense that Ly-1 B cells sorted from these animals spontaneously secrete much more IgM in vitro than BALB/c Ly-1 B cells sorted and cultured at the same density (11) .
Continuing these studies, we present evidence here defining the role that Ly-1 B cells play in autoimmunity. We show (i) that FACS-sorted Ly-1 B cells from LPS-stimulated BALB/c mice are responsible for essentially all of the IgM autoantibody produced to bromelain-treated mouse erythrocytes; (ii) that the spontaneously secreted IgM from FACSsorted NZB Ly-1 B cells contains typical NZB autoantibodies reactive with DNA and with thymocyte cell surface antigen(s); and (iii) that although Ly-1 B cells produce most of the IgM autoantibodies produced to the above antigens, they produce only minimal IgM responses to exogenous antigens such as sheep erythrocytes, 2,4,6-trinitrophenyl-conjugated keyhole limpet hemocyanin (TNP-KLH), and TNP-Ficoll.
Finally (11) . In this particular experiment, either bi-conjugated monoclonal rat anti-Lyt-2 (53-6.7) or mouse anti-Igh-5a(10-4.2) was also used together with Flanti-IgM. Sorted cell fractions were always reanalyzed to check the purity in each expected region.
Plaque-Forming Cells (PFC). Bromelain-treated mouse erythrocytes (brmRBC) were prepared by the method of Cunningham (5) . A 50% suspension of erythrocytes from peripheral blood of 2-month-old BALB/c mice was incubated in a bromelain (Sigma) solution in phosphate-buffered saline at a final concentration of 10 mg/ml, at 37°C for 30 min. TNP coupling to SRBC has been described elsewhere (14) and was used for anti-TNP PFC. Both PFC were developed by using guinea pig complement in Cunningham chambers (15) .
Cell Culture and Assays for Autoantibody in the Secreted Culture Supernatant. Spontaneous secretion of IgM was obtained from the 6-day culture of cells from NZB spleen in RPMI 1640 medium (Irvine Scientific) supplemented with 10% fetal calf serum and 50 ,M 2-mercaptoethanol. The secreted IgM level was determined by a competitive solidphase radioimmunoassay (RIA) (11) . Autoantibodies in the culture supernatants were measured by an enzyme-linked immunosorbent assay (ELISA) described previously (16) for single-stranded DNA (ss DNA) and modified slightly to allow measurement of anti-T cell antibodies.
RESULTS
Detecting and Sorting Ly-1 B Cells from BALB/c Mice. The increased frequency of Ly-1 B cells in NZB spleen (11, 12) makes the splenic NZB Ly-1 B population relatively easy to visualize on two-color FACS-VAX contour plots that display analyses of cells stained with anti-IgM and anti-Ly-1. The frequency of Ly-1 B cells in BALB/c spleen, in contrast, is too low to visualize with analysis conditions that clearly reveal the NZB population (see Fig. 1 ). Thus to measure the Ly-1 B-cell frequencies and to sort Ly-1 B cells from BALB/c (and other normal mouse strains), we define a set of FACS gates that encompass the splenic NZB Ly-1 Bcell population, and we use these gates for sorting and analysis of BALB/c and NZB cell suspensions in the experiments described below.
BALB/c Ly-1 B Cells Secrete IgM Autoantibodies. BALB/c mice normally have small numbers of splenic PFC that produce IgM autoantibodies to cryptic determinant(s) revealed on brmRBC. The frequency of these PFC, however, increases rapidly after in vivo LPS stimulation and reaches a maximum within 1-3 days (6, 17). Since we suspected that the cells responsible for this IgM autoantibody response in BALB/c might be related to the Ly-1 B cells that spontaneously secrete IgM in NZB mice, we sorted the Ly-1+ and Ly-1-B cells from BALB/c spleen 1 day after LPS stimulation and tested the sorted populations for the presence of direct (IgM) anti-brmRBC PFC.
These FACS sorting studies demonstrate clearly that the BALB/c anti-brmRBC PFC response is mediated by the Ly-1 B-cell subpopulation (see Fig. 2 ). That is, anti-brmRBC PFC activity is highly enriched in the sorted Ly-1 B-cell population and essentially depleted from the IgM+, Ly-1-population. Furthermore, very little anti-brmRBC PFC activity is recovered in a control population stained with a comparably prepared monoclonal antibody of the same isotype (anti-Lyt-2) and sorted with the same gates as the Ly-1 B population (see sort 2, lower half of Fig. 2 internal control for the specificity of the ELISA used to measure supernatant IgM autoantibody levels. That is, the demonstration that Ly-1+ B cells produce substantially more IgM autoantibody than Ly-1-B cells in this experiment is based directly on comparisons between supernatants that should yield equivalent levels of nonspecific IgM binding. 1 B cells. Nearly all of the anti-SRBC PFC in SRBC-immunized NZB mice were recovered in the Ly-1-splenic B cell population and the PFC found in the Ly-1 B population were attributable to contamination with Ly-1-cells (11) . Data presented in Table 2 confirm and extend these findings. Ly-1-B cells sorted from NZB animals stimulated with TNPFicoll, TNP-KLH, or TNP-LPS contain virtually all of the direct anti-TNP PFC found in unseparated spleen. A few anti-TNP PFC (1-3% of the total response) are recovered in the Ly-1 B cell population, but the frequency of these PFC is commensurate with the contamination of the Ly-1 B population with Ly-1-B cells.
These data, however, should not be interpreted as indicating that Ly-1 B cells cannot be stimulated to produce antibodies to exogenously introduced antigens. As Table 2 also shows, TNP presented on Brucella abortus stimulates substantial numbers of IgM anti-TNP PFC in the Ly-1 B population. Thus Ly-1 B cells are quite capable of producing antibodies to TNP (and presumably to other epitopes) but apparently do not do so unless presented with the epitope on certain carriers. Fig. 3 ) that has high levels of surface IgM and low levels of surface IgD. This subpopulation (18) contains virtually all of the Ly-1 B cells in spleen (11) . It does not increase significantly in frequency after immunization (data not shown) and does not contain significant numbers of IgM anti-TNP PFC (see Fig. 3 ). The subpopulation enriched for anti-TNP PFC, in contrast, is usually too rare to detect in nonimmunized animals but tends to be detectable several days after immunization in spleen and in lymph nodes that drain the immunization site. This subpopulation (labeled IV in Fig. 3 Data from these experiments demonstrate clearly that LPS activation does not stimulate the appearance of Ly-1 on cells that persist in culture. After 5 days in culture with LPS, the unseparated spleen cell cultures and the cultures containing sorted Ly-1-cells showed substantial numbers of activated cells (see Fig. 4 ). However, less than 1% of the activated cells (that fell within the "gates" shown in Fig. 4 The production of all autoantibodies is probably not due to the activity of this B-cell subpopulation. IgG autoantibodies, for example, are commonly produced in older NZB mice and in other autoimmune mice (16) . These antibodies are likely to be produced by IgG-bearing B cells rather than by Ly-1 B cells, which express IgM and IgD. Such IgG-producing cells could be related to Ly-1 B cells, but we have no reason to think that they are. Therefore, we suggest that Ly-1 B cells are responsible for producing certain (perhaps most) IgM autoantibodies but that other B cells also contribute to autoimmunity.
These limitations do not detract from the potential importance of the data presented here vis-A-vis the development of new therapies for autoimmune diseases in humans. In essence, the concentration of certain IgM autoantibody-producing functions into a small, phenotypically distinct B cell population in both autoimmune and normal mice opens the possibility that an analogous B cell subset might be found in humans with particular autoimmune diseases. If so, then finding methods to selectively eliminate this subpopulation might allow the treatment of such diseases without compromising other B-cell functions in the treated individual.
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